nodes	percent_of_prediction	percent_of_DWPC	metapath
Daunorubicin—CYP1A1—Clobetasol propionate—psoriasis	0.0682	0.0946	CbGbCtD
Daunorubicin—ABCC10—Cyclosporine—psoriasis	0.0654	0.0907	CbGbCtD
Daunorubicin—CYP1A1—Methoxsalen—psoriasis	0.0358	0.0497	CbGbCtD
Daunorubicin—ABCB11—Cyclosporine—psoriasis	0.0355	0.0493	CbGbCtD
Daunorubicin—ABCC10—Methotrexate—psoriasis	0.0346	0.048	CbGbCtD
Daunorubicin—CYP3A5—Beclomethasone—psoriasis	0.031	0.043	CbGbCtD
Daunorubicin—CYP1A2—Clobetasol propionate—psoriasis	0.0305	0.0422	CbGbCtD
Daunorubicin—ABCC1—Cyclosporine—psoriasis	0.0252	0.035	CbGbCtD
Daunorubicin—ABCC2—Mycophenolate mofetil—psoriasis	0.0246	0.0342	CbGbCtD
Daunorubicin—CYP1A1—Cholecalciferol—psoriasis	0.0237	0.0329	CbGbCtD
Daunorubicin—ABCB11—Dexamethasone—psoriasis	0.0234	0.0325	CbGbCtD
Daunorubicin—CYP1B1—Dexamethasone—psoriasis	0.0234	0.0325	CbGbCtD
Daunorubicin—ABCG2—Mycophenolate mofetil—psoriasis	0.0223	0.0309	CbGbCtD
Daunorubicin—ABCC2—Cyclosporine—psoriasis	0.0187	0.0259	CbGbCtD
Daunorubicin—ABCG2—Hydrocortisone—psoriasis	0.0179	0.0248	CbGbCtD
Daunorubicin—ABCG2—Cyclosporine—psoriasis	0.0169	0.0234	CbGbCtD
Daunorubicin—CYP1A2—Methoxsalen—psoriasis	0.016	0.0222	CbGbCtD
Daunorubicin—ABCC1—Methotrexate—psoriasis	0.0134	0.0185	CbGbCtD
Daunorubicin—CYP3A5—Mycophenolate mofetil—psoriasis	0.0123	0.0171	CbGbCtD
Daunorubicin—ABCC2—Dexamethasone—psoriasis	0.0123	0.0171	CbGbCtD
Daunorubicin—ABCG2—Dexamethasone—psoriasis	0.0111	0.0154	CbGbCtD
Daunorubicin—CYP3A4—Calcitriol—psoriasis	0.0108	0.015	CbGbCtD
Daunorubicin—CYP1A1—Dexamethasone—psoriasis	0.0103	0.0142	CbGbCtD
Daunorubicin—CYP3A5—Hydrocortisone—psoriasis	0.00991	0.0137	CbGbCtD
Daunorubicin—ABCC2—Methotrexate—psoriasis	0.00989	0.0137	CbGbCtD
Daunorubicin—CYP3A5—Cyclosporine—psoriasis	0.00936	0.013	CbGbCtD
Daunorubicin—ABCG2—Methotrexate—psoriasis	0.00894	0.0124	CbGbCtD
Daunorubicin—CYP3A4—Methoxsalen—psoriasis	0.00838	0.0116	CbGbCtD
Daunorubicin—ABCB1—Mycophenolate mofetil—psoriasis	0.00804	0.0111	CbGbCtD
Daunorubicin—ABCB1—Betamethasone—psoriasis	0.00689	0.00956	CbGbCtD
Daunorubicin—ABCB1—Prednisolone—psoriasis	0.0068	0.00944	CbGbCtD
Daunorubicin—ABCB1—Hydrocortisone—psoriasis	0.00645	0.00894	CbGbCtD
Daunorubicin—ABCB1—Prednisone—psoriasis	0.00642	0.00891	CbGbCtD
Daunorubicin—CYP3A5—Dexamethasone—psoriasis	0.00616	0.00855	CbGbCtD
Daunorubicin—ABCB1—Cyclosporine—psoriasis	0.00609	0.00845	CbGbCtD
Daunorubicin—CYP3A4—Cholecalciferol—psoriasis	0.00555	0.0077	CbGbCtD
Daunorubicin—CYP3A4—Triamcinolone—psoriasis	0.00481	0.00668	CbGbCtD
Daunorubicin—CYP3A4—Mycophenolate mofetil—psoriasis	0.00481	0.00668	CbGbCtD
Daunorubicin—ABCC6—dermis—psoriasis	0.00453	0.575	CbGeAlD
Daunorubicin—CYP3A4—Betamethasone—psoriasis	0.00413	0.00573	CbGbCtD
Daunorubicin—CYP3A4—Prednisolone—psoriasis	0.00408	0.00565	CbGbCtD
Daunorubicin—ABCB1—Dexamethasone—psoriasis	0.00401	0.00556	CbGbCtD
Daunorubicin—CYP3A4—Hydrocortisone—psoriasis	0.00386	0.00536	CbGbCtD
Daunorubicin—CYP3A4—Prednisone—psoriasis	0.00385	0.00534	CbGbCtD
Daunorubicin—CYP3A4—Cyclosporine—psoriasis	0.00365	0.00506	CbGbCtD
Daunorubicin—ABCB1—Methotrexate—psoriasis	0.00322	0.00447	CbGbCtD
Daunorubicin—CYP3A4—Dexamethasone—psoriasis	0.0024	0.00333	CbGbCtD
Daunorubicin—Doxorubicin—NOS2—psoriasis	0.00159	1	CrCbGaD
Daunorubicin—CYP1A1—skin epidermis—psoriasis	0.000602	0.0764	CbGeAlD
Daunorubicin—YWHAG—tendon—psoriasis	0.000423	0.0537	CbGeAlD
Daunorubicin—TOP2B—tendon—psoriasis	0.000408	0.0518	CbGeAlD
Daunorubicin—POR—tendon—psoriasis	0.000322	0.0409	CbGeAlD
Daunorubicin—TOP2A—tendon—psoriasis	0.0003	0.0381	CbGeAlD
Daunorubicin—CYP1B1—skin of body—psoriasis	0.000264	0.0335	CbGeAlD
Daunorubicin—ABCC10—tendon—psoriasis	0.000255	0.0324	CbGeAlD
Daunorubicin—TOP2A—Methyltestosterone—Hydrocortisone—psoriasis	0.000243	0.258	CbGdCrCtD
Daunorubicin—TOP2A—Methyltestosterone—Prednisone—psoriasis	0.000209	0.222	CbGdCrCtD
Daunorubicin—ABCC2—tendon—psoriasis	0.000205	0.026	CbGeAlD
Daunorubicin—TOP2A—Methyltestosterone—Prednisolone—psoriasis	0.000204	0.217	CbGdCrCtD
Daunorubicin—CYP1B1—tendon—psoriasis	0.000201	0.0255	CbGeAlD
Daunorubicin—CYP1A1—skin of body—psoriasis	0.000187	0.0237	CbGeAlD
Daunorubicin—ABCC1—tendon—psoriasis	0.000181	0.0229	CbGeAlD
Daunorubicin—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.000168	0.00356	CbGpPWpGaD
Daunorubicin—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.000165	0.00351	CbGpPWpGaD
Daunorubicin—ABCC10—Transmembrane transport of small molecules—CP—psoriasis	0.000164	0.00348	CbGpPWpGaD
Daunorubicin—TOP2A—Norethindrone—Hydrocortisone—psoriasis	0.000159	0.168	CbGdCrCtD
Daunorubicin—YWHAG—LKB1 signaling events—TP53—psoriasis	0.000159	0.00337	CbGpPWpGaD
Daunorubicin—CYP1A1—Biological oxidations—CYP2S1—psoriasis	0.000158	0.00336	CbGpPWpGaD
Daunorubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—psoriasis	0.000157	0.00334	CbGpPWpGaD
Daunorubicin—ABCC10—Transmembrane transport of small molecules—CARM1—psoriasis	0.000156	0.00332	CbGpPWpGaD
Daunorubicin—CYP1A1—Metapathway biotransformation—CYP2S1—psoriasis	0.000156	0.00332	CbGpPWpGaD
Daunorubicin—CYP1A1—Estrogen Receptor Pathway—STAT3—psoriasis	0.000156	0.00331	CbGpPWpGaD
Daunorubicin—YWHAG—Cell Cycle, Mitotic—PTTG1—psoriasis	0.000155	0.0033	CbGpPWpGaD
Daunorubicin—CYP1A1—Melatonin metabolism and effects—APOE—psoriasis	0.000154	0.00326	CbGpPWpGaD
Daunorubicin—ABCC2—NRF2 pathway—TGFA—psoriasis	0.00015	0.00318	CbGpPWpGaD
Daunorubicin—CYP1B1—Melatonin metabolism and effects—NFKB1—psoriasis	0.000148	0.00315	CbGpPWpGaD
Daunorubicin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000147	0.00312	CbGpPWpGaD
Daunorubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—psoriasis	0.000146	0.0031	CbGpPWpGaD
Daunorubicin—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000145	0.00307	CbGpPWpGaD
Daunorubicin—TOP2A—Gastric Cancer Network 2—TP53—psoriasis	0.000144	0.00306	CbGpPWpGaD
Daunorubicin—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000139	0.00296	CbGpPWpGaD
Daunorubicin—YWHAG—Cell Cycle—PTTG1—psoriasis	0.000139	0.00295	CbGpPWpGaD
Daunorubicin—XDH—Selenium Micronutrient Network—IFNG—psoriasis	0.000137	0.00291	CbGpPWpGaD
Daunorubicin—CYP1A1—Tryptophan metabolism—CAT—psoriasis	0.000137	0.0029	CbGpPWpGaD
Daunorubicin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000135	0.00287	CbGpPWpGaD
Daunorubicin—NR5A1—Generic Transcription Pathway—VDR—psoriasis	0.000131	0.00278	CbGpPWpGaD
Daunorubicin—TOP2A—Levonorgestrel—Hydrocortisone—psoriasis	0.000126	0.134	CbGdCrCtD
Daunorubicin—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000123	0.00262	CbGpPWpGaD
Daunorubicin—TOP2A—Mitotic G1-G1/S phases—PCNA—psoriasis	0.000121	0.00256	CbGpPWpGaD
Daunorubicin—YWHAG—ErbB1 downstream signaling—JUN—psoriasis	0.000118	0.0025	CbGpPWpGaD
Daunorubicin—ABCG2—HIF-1-alpha transcription factor network—LEP—psoriasis	0.000118	0.0025	CbGpPWpGaD
Daunorubicin—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000115	0.00244	CbGpPWpGaD
Daunorubicin—XDH—Selenium Micronutrient Network—NFKB1—psoriasis	0.000114	0.00242	CbGpPWpGaD
Daunorubicin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000113	0.00239	CbGpPWpGaD
Daunorubicin—CYP1A1—PPARA activates gene expression—CARM1—psoriasis	0.000111	0.00235	CbGpPWpGaD
Daunorubicin—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriasis	0.00011	0.00233	CbGpPWpGaD
Daunorubicin—TOP2A—Cell Cycle, Mitotic—PTTG1—psoriasis	0.000109	0.00231	CbGpPWpGaD
Daunorubicin—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000108	0.0023	CbGpPWpGaD
Daunorubicin—ABCG2—HIF-2-alpha transcription factor network—VEGFA—psoriasis	0.000108	0.00229	CbGpPWpGaD
Daunorubicin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000108	0.00229	CbGpPWpGaD
Daunorubicin—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000108	0.00228	CbGpPWpGaD
Daunorubicin—ABCB1—Allograft Rejection—IL13—psoriasis	0.000107	0.00227	CbGpPWpGaD
Daunorubicin—CYP1B1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000107	0.00226	CbGpPWpGaD
Daunorubicin—NR5A1—Gene Expression—CARM1—psoriasis	0.000106	0.00224	CbGpPWpGaD
Daunorubicin—CYP1B1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	0.000103	0.00218	CbGpPWpGaD
Daunorubicin—YWHAG—PDGFR-beta signaling pathway—JUN—psoriasis	0.000102	0.00217	CbGpPWpGaD
Daunorubicin—YWHAG—ErbB1 downstream signaling—STAT3—psoriasis	0.000102	0.00216	CbGpPWpGaD
Daunorubicin—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000101	0.00214	CbGpPWpGaD
Daunorubicin—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	9.96e-05	0.00212	CbGpPWpGaD
Daunorubicin—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	9.94e-05	0.00211	CbGpPWpGaD
Daunorubicin—NR5A1—Developmental Biology—LEP—psoriasis	9.87e-05	0.0021	CbGpPWpGaD
Daunorubicin—ABCB1—Allograft Rejection—IL17A—psoriasis	9.84e-05	0.00209	CbGpPWpGaD
Daunorubicin—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	9.79e-05	0.00208	CbGpPWpGaD
Daunorubicin—TOP2A—Cell Cycle—PTTG1—psoriasis	9.71e-05	0.00206	CbGpPWpGaD
Daunorubicin—XDH—Metabolism—NDUFA5—psoriasis	9.66e-05	0.00205	CbGpPWpGaD
Daunorubicin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.41e-05	0.002	CbGpPWpGaD
Daunorubicin—CYP1B1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	9.31e-05	0.00198	CbGpPWpGaD
Daunorubicin—YWHAG—SIDS Susceptibility Pathways—CXCL8—psoriasis	9.21e-05	0.00196	CbGpPWpGaD
Daunorubicin—ABCB1—Allograft Rejection—IL12B—psoriasis	9.15e-05	0.00194	CbGpPWpGaD
Daunorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	9.15e-05	0.00194	CbGpPWpGaD
Daunorubicin—CYP1A1—Melatonin metabolism and effects—NFKB1—psoriasis	9.13e-05	0.00194	CbGpPWpGaD
Daunorubicin—NR5A1—Generic Transcription Pathway—PPARG—psoriasis	9.13e-05	0.00194	CbGpPWpGaD
Daunorubicin—ABCB1—Allograft Rejection—HLA-E—psoriasis	8.93e-05	0.0019	CbGpPWpGaD
Daunorubicin—CYP1A1—Oxidative Stress—NFKB1—psoriasis	8.89e-05	0.00189	CbGpPWpGaD
Daunorubicin—XDH—Selenium Micronutrient Network—TNF—psoriasis	8.86e-05	0.00188	CbGpPWpGaD
Daunorubicin—YWHAG—PDGFR-beta signaling pathway—STAT3—psoriasis	8.85e-05	0.00188	CbGpPWpGaD
Daunorubicin—CYP1A2—Tryptophan metabolism—CAT—psoriasis	8.71e-05	0.00185	CbGpPWpGaD
Daunorubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—JUN—psoriasis	8.61e-05	0.00183	CbGpPWpGaD
Daunorubicin—NR5A1—Developmental Biology—PPARG—psoriasis	8.6e-05	0.00182	CbGpPWpGaD
Daunorubicin—YWHAG—SIDS Susceptibility Pathways—JUN—psoriasis	8.57e-05	0.00182	CbGpPWpGaD
Daunorubicin—SLC22A2—SLC-mediated transmembrane transport—CP—psoriasis	8.52e-05	0.00181	CbGpPWpGaD
Daunorubicin—ABCG2—Fluoropyrimidine Activity—TP53—psoriasis	8.35e-05	0.00177	CbGpPWpGaD
Daunorubicin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	8.32e-05	0.00177	CbGpPWpGaD
Daunorubicin—Conjunctivitis—Methotrexate—psoriasis	8.3e-05	0.000374	CcSEcCtD
Daunorubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—NFKB1—psoriasis	8.29e-05	0.00176	CbGpPWpGaD
Daunorubicin—Malaise—Betamethasone—psoriasis	8.26e-05	0.000373	CcSEcCtD
Daunorubicin—Malaise—Dexamethasone—psoriasis	8.26e-05	0.000373	CcSEcCtD
Daunorubicin—YWHAG—SIDS Susceptibility Pathways—NFKB1—psoriasis	8.25e-05	0.00175	CbGpPWpGaD
Daunorubicin—Anaphylactic shock—Triamcinolone—psoriasis	8.24e-05	0.000372	CcSEcCtD
Daunorubicin—Oedema—Triamcinolone—psoriasis	8.24e-05	0.000372	CcSEcCtD
Daunorubicin—Syncope—Betamethasone—psoriasis	8.22e-05	0.000371	CcSEcCtD
Daunorubicin—Syncope—Dexamethasone—psoriasis	8.22e-05	0.000371	CcSEcCtD
Daunorubicin—Constipation—Mycophenolate mofetil—psoriasis	8.22e-05	0.000371	CcSEcCtD
Daunorubicin—Pain—Mycophenolate mofetil—psoriasis	8.22e-05	0.000371	CcSEcCtD
Daunorubicin—XDH—Metabolism—CYP2S1—psoriasis	8.21e-05	0.00174	CbGpPWpGaD
Daunorubicin—Arrhythmia—Prednisone—psoriasis	8.19e-05	0.00037	CcSEcCtD
Daunorubicin—Infection—Triamcinolone—psoriasis	8.19e-05	0.00037	CcSEcCtD
Daunorubicin—Feeling abnormal—Cyclosporine—psoriasis	8.12e-05	0.000366	CcSEcCtD
Daunorubicin—Shock—Triamcinolone—psoriasis	8.11e-05	0.000366	CcSEcCtD
Daunorubicin—Insomnia—Prednisolone—psoriasis	8.11e-05	0.000366	CcSEcCtD
Daunorubicin—Alopecia—Prednisone—psoriasis	8.1e-05	0.000366	CcSEcCtD
Daunorubicin—Gastrointestinal pain—Cyclosporine—psoriasis	8.06e-05	0.000364	CcSEcCtD
Daunorubicin—Loss of consciousness—Betamethasone—psoriasis	8.06e-05	0.000364	CcSEcCtD
Daunorubicin—Loss of consciousness—Dexamethasone—psoriasis	8.06e-05	0.000364	CcSEcCtD
Daunorubicin—Dizziness—Mycophenolic acid—psoriasis	8.05e-05	0.000363	CcSEcCtD
Daunorubicin—Tachycardia—Triamcinolone—psoriasis	8.05e-05	0.000363	CcSEcCtD
Daunorubicin—Erythema—Prednisone—psoriasis	7.98e-05	0.00036	CcSEcCtD
Daunorubicin—CYP1B1—Aryl Hydrocarbon Receptor—TNF—psoriasis	7.98e-05	0.00169	CbGpPWpGaD
Daunorubicin—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	7.98e-05	0.00169	CbGpPWpGaD
Daunorubicin—Musculoskeletal discomfort—Hydrocortisone—psoriasis	7.98e-05	0.00036	CcSEcCtD
Daunorubicin—Hyperhidrosis—Triamcinolone—psoriasis	7.97e-05	0.00036	CcSEcCtD
Daunorubicin—YWHAG—Cell Cycle—TP53—psoriasis	7.94e-05	0.00169	CbGpPWpGaD
Daunorubicin—Convulsion—Dexamethasone—psoriasis	7.94e-05	0.000358	CcSEcCtD
Daunorubicin—Convulsion—Betamethasone—psoriasis	7.94e-05	0.000358	CcSEcCtD
Daunorubicin—Feeling abnormal—Mycophenolate mofetil—psoriasis	7.92e-05	0.000357	CcSEcCtD
Daunorubicin—Insomnia—Hydrocortisone—psoriasis	7.92e-05	0.000357	CcSEcCtD
Daunorubicin—TOP2A—Circadian rythm related genes—LEP—psoriasis	7.92e-05	0.00168	CbGpPWpGaD
Daunorubicin—Hypertension—Betamethasone—psoriasis	7.91e-05	0.000357	CcSEcCtD
Daunorubicin—Hypertension—Dexamethasone—psoriasis	7.91e-05	0.000357	CcSEcCtD
Daunorubicin—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	7.86e-05	0.000355	CcSEcCtD
Daunorubicin—Urticaria—Cyclosporine—psoriasis	7.83e-05	0.000353	CcSEcCtD
Daunorubicin—Myalgia—Betamethasone—psoriasis	7.8e-05	0.000352	CcSEcCtD
Daunorubicin—Myalgia—Dexamethasone—psoriasis	7.8e-05	0.000352	CcSEcCtD
Daunorubicin—CYP3A4—Biological oxidations—CYP2S1—psoriasis	7.8e-05	0.00166	CbGpPWpGaD
Daunorubicin—Body temperature increased—Cyclosporine—psoriasis	7.79e-05	0.000351	CcSEcCtD
Daunorubicin—Abdominal pain—Cyclosporine—psoriasis	7.79e-05	0.000351	CcSEcCtD
Daunorubicin—Anxiety—Betamethasone—psoriasis	7.78e-05	0.000351	CcSEcCtD
Daunorubicin—Anxiety—Dexamethasone—psoriasis	7.78e-05	0.000351	CcSEcCtD
Daunorubicin—Vomiting—Mycophenolic acid—psoriasis	7.74e-05	0.000349	CcSEcCtD
Daunorubicin—Discomfort—Betamethasone—psoriasis	7.71e-05	0.000348	CcSEcCtD
Daunorubicin—Discomfort—Dexamethasone—psoriasis	7.71e-05	0.000348	CcSEcCtD
Daunorubicin—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	7.69e-05	0.00163	CbGpPWpGaD
Daunorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	7.69e-05	0.00163	CbGpPWpGaD
Daunorubicin—Rash—Mycophenolic acid—psoriasis	7.68e-05	0.000347	CcSEcCtD
Daunorubicin—Dermatitis—Mycophenolic acid—psoriasis	7.67e-05	0.000346	CcSEcCtD
Daunorubicin—Pain—Prednisolone—psoriasis	7.67e-05	0.000346	CcSEcCtD
Daunorubicin—Urticaria—Mycophenolate mofetil—psoriasis	7.63e-05	0.000345	CcSEcCtD
Daunorubicin—Headache—Mycophenolic acid—psoriasis	7.63e-05	0.000344	CcSEcCtD
Daunorubicin—Decreased appetite—Hydrocortisone—psoriasis	7.61e-05	0.000344	CcSEcCtD
Daunorubicin—Abdominal pain—Mycophenolate mofetil—psoriasis	7.6e-05	0.000343	CcSEcCtD
Daunorubicin—Body temperature increased—Mycophenolate mofetil—psoriasis	7.6e-05	0.000343	CcSEcCtD
Daunorubicin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	7.59e-05	0.00161	CbGpPWpGaD
Daunorubicin—Fatigue—Hydrocortisone—psoriasis	7.55e-05	0.000341	CcSEcCtD
Daunorubicin—NR5A1—Developmental Biology—TYK2—psoriasis	7.53e-05	0.0016	CbGpPWpGaD
Daunorubicin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.51e-05	0.00159	CbGpPWpGaD
Daunorubicin—Musculoskeletal discomfort—Triamcinolone—psoriasis	7.51e-05	0.000339	CcSEcCtD
Daunorubicin—Pain—Hydrocortisone—psoriasis	7.49e-05	0.000338	CcSEcCtD
Daunorubicin—YWHAG—SIDS Susceptibility Pathways—VEGFA—psoriasis	7.48e-05	0.00159	CbGpPWpGaD
Daunorubicin—Anaphylactic shock—Dexamethasone—psoriasis	7.48e-05	0.000338	CcSEcCtD
Daunorubicin—Oedema—Dexamethasone—psoriasis	7.48e-05	0.000338	CcSEcCtD
Daunorubicin—Anaphylactic shock—Betamethasone—psoriasis	7.48e-05	0.000338	CcSEcCtD
Daunorubicin—Oedema—Betamethasone—psoriasis	7.48e-05	0.000338	CcSEcCtD
Daunorubicin—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	7.46e-05	0.00158	CbGpPWpGaD
Daunorubicin—Insomnia—Triamcinolone—psoriasis	7.46e-05	0.000337	CcSEcCtD
Daunorubicin—Infection—Betamethasone—psoriasis	7.43e-05	0.000335	CcSEcCtD
Daunorubicin—Infection—Dexamethasone—psoriasis	7.43e-05	0.000335	CcSEcCtD
Daunorubicin—Ill-defined disorder—Prednisone—psoriasis	7.41e-05	0.000334	CcSEcCtD
Daunorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	7.39e-05	0.00157	CbGpPWpGaD
Daunorubicin—Feeling abnormal—Prednisolone—psoriasis	7.39e-05	0.000333	CcSEcCtD
Daunorubicin—Visual impairment—Methotrexate—psoriasis	7.38e-05	0.000333	CcSEcCtD
Daunorubicin—TOP2A—Circadian rythm related genes—NOS2—psoriasis	7.38e-05	0.00157	CbGpPWpGaD
Daunorubicin—Anaemia—Prednisone—psoriasis	7.38e-05	0.000333	CcSEcCtD
Daunorubicin—Shock—Betamethasone—psoriasis	7.36e-05	0.000332	CcSEcCtD
Daunorubicin—Shock—Dexamethasone—psoriasis	7.36e-05	0.000332	CcSEcCtD
Daunorubicin—Dyspnoea—Triamcinolone—psoriasis	7.35e-05	0.000332	CcSEcCtD
Daunorubicin—Agitation—Prednisone—psoriasis	7.33e-05	0.000331	CcSEcCtD
Daunorubicin—Thrombocytopenia—Dexamethasone—psoriasis	7.32e-05	0.000331	CcSEcCtD
Daunorubicin—Thrombocytopenia—Betamethasone—psoriasis	7.32e-05	0.000331	CcSEcCtD
Daunorubicin—Tachycardia—Betamethasone—psoriasis	7.3e-05	0.000329	CcSEcCtD
Daunorubicin—Tachycardia—Dexamethasone—psoriasis	7.3e-05	0.000329	CcSEcCtD
Daunorubicin—ABCG2—HIF-1-alpha transcription factor network—JUN—psoriasis	7.26e-05	0.00154	CbGpPWpGaD
Daunorubicin—Hypersensitivity—Cyclosporine—psoriasis	7.26e-05	0.000328	CcSEcCtD
Daunorubicin—Nausea—Mycophenolic acid—psoriasis	7.23e-05	0.000326	CcSEcCtD
Daunorubicin—Hyperhidrosis—Betamethasone—psoriasis	7.23e-05	0.000326	CcSEcCtD
Daunorubicin—Hyperhidrosis—Dexamethasone—psoriasis	7.23e-05	0.000326	CcSEcCtD
Daunorubicin—Feeling abnormal—Hydrocortisone—psoriasis	7.21e-05	0.000326	CcSEcCtD
Daunorubicin—Malaise—Prednisone—psoriasis	7.2e-05	0.000325	CcSEcCtD
Daunorubicin—Gastrointestinal pain—Hydrocortisone—psoriasis	7.16e-05	0.000323	CcSEcCtD
Daunorubicin—Syncope—Prednisone—psoriasis	7.16e-05	0.000323	CcSEcCtD
Daunorubicin—XDH—Selenium Micronutrient Network—IL6—psoriasis	7.15e-05	0.00152	CbGpPWpGaD
Daunorubicin—Tinnitus—Methotrexate—psoriasis	7.14e-05	0.000322	CcSEcCtD
Daunorubicin—Anorexia—Dexamethasone—psoriasis	7.13e-05	0.000322	CcSEcCtD
Daunorubicin—Anorexia—Betamethasone—psoriasis	7.13e-05	0.000322	CcSEcCtD
Daunorubicin—Urticaria—Prednisolone—psoriasis	7.12e-05	0.000321	CcSEcCtD
Daunorubicin—ABCB11—Metabolism—NDUFA5—psoriasis	7.12e-05	0.00151	CbGpPWpGaD
Daunorubicin—Cardiac disorder—Methotrexate—psoriasis	7.11e-05	0.000321	CcSEcCtD
Daunorubicin—Fatigue—Triamcinolone—psoriasis	7.11e-05	0.000321	CcSEcCtD
Daunorubicin—Hypersensitivity—Mycophenolate mofetil—psoriasis	7.08e-05	0.00032	CcSEcCtD
Daunorubicin—Asthenia—Cyclosporine—psoriasis	7.07e-05	0.000319	CcSEcCtD
Daunorubicin—Pain—Triamcinolone—psoriasis	7.05e-05	0.000318	CcSEcCtD
Daunorubicin—Loss of consciousness—Prednisone—psoriasis	7.01e-05	0.000317	CcSEcCtD
Daunorubicin—Pruritus—Cyclosporine—psoriasis	6.97e-05	0.000315	CcSEcCtD
Daunorubicin—Urticaria—Hydrocortisone—psoriasis	6.95e-05	0.000314	CcSEcCtD
Daunorubicin—Body temperature increased—Hydrocortisone—psoriasis	6.92e-05	0.000312	CcSEcCtD
Daunorubicin—Abdominal pain—Hydrocortisone—psoriasis	6.92e-05	0.000312	CcSEcCtD
Daunorubicin—Convulsion—Prednisone—psoriasis	6.92e-05	0.000312	CcSEcCtD
Daunorubicin—TOP2A—Circadian rythm related genes—PPARG—psoriasis	6.9e-05	0.00146	CbGpPWpGaD
Daunorubicin—Asthenia—Mycophenolate mofetil—psoriasis	6.89e-05	0.000311	CcSEcCtD
Daunorubicin—Hypertension—Prednisone—psoriasis	6.89e-05	0.000311	CcSEcCtD
Daunorubicin—Chills—Methotrexate—psoriasis	6.88e-05	0.00031	CcSEcCtD
Daunorubicin—Musculoskeletal discomfort—Dexamethasone—psoriasis	6.81e-05	0.000308	CcSEcCtD
Daunorubicin—Musculoskeletal discomfort—Betamethasone—psoriasis	6.81e-05	0.000308	CcSEcCtD
Daunorubicin—Pruritus—Mycophenolate mofetil—psoriasis	6.8e-05	0.000307	CcSEcCtD
Daunorubicin—Arthralgia—Prednisone—psoriasis	6.79e-05	0.000307	CcSEcCtD
Daunorubicin—Myalgia—Prednisone—psoriasis	6.79e-05	0.000307	CcSEcCtD
Daunorubicin—Feeling abnormal—Triamcinolone—psoriasis	6.79e-05	0.000307	CcSEcCtD
Daunorubicin—Anxiety—Prednisone—psoriasis	6.77e-05	0.000306	CcSEcCtD
Daunorubicin—Alopecia—Methotrexate—psoriasis	6.77e-05	0.000306	CcSEcCtD
Daunorubicin—Insomnia—Dexamethasone—psoriasis	6.77e-05	0.000305	CcSEcCtD
Daunorubicin—Insomnia—Betamethasone—psoriasis	6.77e-05	0.000305	CcSEcCtD
Daunorubicin—Diarrhoea—Cyclosporine—psoriasis	6.74e-05	0.000304	CcSEcCtD
Daunorubicin—CYP3A4—Tryptophan metabolism—CAT—psoriasis	6.73e-05	0.00143	CbGpPWpGaD
Daunorubicin—Discomfort—Prednisone—psoriasis	6.71e-05	0.000303	CcSEcCtD
Daunorubicin—ABCB1—Allograft Rejection—IL10—psoriasis	6.69e-05	0.00142	CbGpPWpGaD
Daunorubicin—Erythema—Methotrexate—psoriasis	6.67e-05	0.000301	CcSEcCtD
Daunorubicin—ABCB11—Metabolism of lipids and lipoproteins—CARM1—psoriasis	6.64e-05	0.00141	CbGpPWpGaD
Daunorubicin—Hypersensitivity—Prednisolone—psoriasis	6.6e-05	0.000298	CcSEcCtD
Daunorubicin—Diarrhoea—Mycophenolate mofetil—psoriasis	6.57e-05	0.000297	CcSEcCtD
Daunorubicin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	6.56e-05	0.00139	CbGpPWpGaD
Daunorubicin—Urticaria—Triamcinolone—psoriasis	6.55e-05	0.000296	CcSEcCtD
Daunorubicin—Dysgeusia—Methotrexate—psoriasis	6.53e-05	0.000295	CcSEcCtD
Daunorubicin—Body temperature increased—Triamcinolone—psoriasis	6.52e-05	0.000294	CcSEcCtD
Daunorubicin—Dizziness—Cyclosporine—psoriasis	6.51e-05	0.000294	CcSEcCtD
Daunorubicin—Anaphylactic shock—Prednisone—psoriasis	6.51e-05	0.000294	CcSEcCtD
Daunorubicin—Oedema—Prednisone—psoriasis	6.51e-05	0.000294	CcSEcCtD
Daunorubicin—ABCB1—Allograft Rejection—IL4—psoriasis	6.51e-05	0.00138	CbGpPWpGaD
Daunorubicin—Decreased appetite—Betamethasone—psoriasis	6.5e-05	0.000293	CcSEcCtD
Daunorubicin—Decreased appetite—Dexamethasone—psoriasis	6.5e-05	0.000293	CcSEcCtD
Daunorubicin—Infection—Prednisone—psoriasis	6.47e-05	0.000292	CcSEcCtD
Daunorubicin—Back pain—Methotrexate—psoriasis	6.45e-05	0.000291	CcSEcCtD
Daunorubicin—Hypersensitivity—Hydrocortisone—psoriasis	6.45e-05	0.000291	CcSEcCtD
Daunorubicin—Fatigue—Dexamethasone—psoriasis	6.45e-05	0.000291	CcSEcCtD
Daunorubicin—Fatigue—Betamethasone—psoriasis	6.45e-05	0.000291	CcSEcCtD
Daunorubicin—YWHAG—Apoptosis—TNF—psoriasis	6.45e-05	0.00137	CbGpPWpGaD
Daunorubicin—YWHAG—SIDS Susceptibility Pathways—TNF—psoriasis	6.41e-05	0.00136	CbGpPWpGaD
Daunorubicin—Shock—Prednisone—psoriasis	6.41e-05	0.000289	CcSEcCtD
Daunorubicin—Pain—Dexamethasone—psoriasis	6.4e-05	0.000289	CcSEcCtD
Daunorubicin—Pain—Betamethasone—psoriasis	6.4e-05	0.000289	CcSEcCtD
Daunorubicin—ABCB1—Allograft Rejection—HLA-B—psoriasis	6.36e-05	0.00135	CbGpPWpGaD
Daunorubicin—Tachycardia—Prednisone—psoriasis	6.36e-05	0.000287	CcSEcCtD
Daunorubicin—Dizziness—Mycophenolate mofetil—psoriasis	6.35e-05	0.000287	CcSEcCtD
Daunorubicin—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	6.35e-05	0.00135	CbGpPWpGaD
Daunorubicin—ABCG2—HIF-1-alpha transcription factor network—VEGFA—psoriasis	6.34e-05	0.00135	CbGpPWpGaD
Daunorubicin—YWHAG—Cell Cycle, Mitotic—PCNA—psoriasis	6.33e-05	0.00134	CbGpPWpGaD
Daunorubicin—CYP1A1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	6.32e-05	0.00134	CbGpPWpGaD
Daunorubicin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—psoriasis	6.31e-05	0.00134	CbGpPWpGaD
Daunorubicin—NR5A1—Gene Expression—VDR—psoriasis	6.31e-05	0.00134	CbGpPWpGaD
Daunorubicin—Hyperhidrosis—Prednisone—psoriasis	6.3e-05	0.000284	CcSEcCtD
Daunorubicin—Asthenia—Hydrocortisone—psoriasis	6.28e-05	0.000284	CcSEcCtD
Daunorubicin—Vomiting—Cyclosporine—psoriasis	6.26e-05	0.000283	CcSEcCtD
Daunorubicin—Rash—Cyclosporine—psoriasis	6.21e-05	0.00028	CcSEcCtD
Daunorubicin—Anorexia—Prednisone—psoriasis	6.21e-05	0.00028	CcSEcCtD
Daunorubicin—Dermatitis—Cyclosporine—psoriasis	6.21e-05	0.00028	CcSEcCtD
Daunorubicin—Pruritus—Hydrocortisone—psoriasis	6.19e-05	0.00028	CcSEcCtD
Daunorubicin—Ill-defined disorder—Methotrexate—psoriasis	6.19e-05	0.000279	CcSEcCtD
Daunorubicin—Headache—Cyclosporine—psoriasis	6.17e-05	0.000279	CcSEcCtD
Daunorubicin—Anaemia—Methotrexate—psoriasis	6.17e-05	0.000278	CcSEcCtD
Daunorubicin—Feeling abnormal—Dexamethasone—psoriasis	6.16e-05	0.000278	CcSEcCtD
Daunorubicin—Feeling abnormal—Betamethasone—psoriasis	6.16e-05	0.000278	CcSEcCtD
Daunorubicin—Gastrointestinal pain—Dexamethasone—psoriasis	6.12e-05	0.000276	CcSEcCtD
Daunorubicin—Gastrointestinal pain—Betamethasone—psoriasis	6.12e-05	0.000276	CcSEcCtD
Daunorubicin—Vomiting—Mycophenolate mofetil—psoriasis	6.11e-05	0.000276	CcSEcCtD
Daunorubicin—Hypersensitivity—Triamcinolone—psoriasis	6.07e-05	0.000274	CcSEcCtD
Daunorubicin—Rash—Mycophenolate mofetil—psoriasis	6.06e-05	0.000273	CcSEcCtD
Daunorubicin—ABCB11—Metabolism—CYP2S1—psoriasis	6.05e-05	0.00129	CbGpPWpGaD
Daunorubicin—Dermatitis—Mycophenolate mofetil—psoriasis	6.05e-05	0.000273	CcSEcCtD
Daunorubicin—Headache—Mycophenolate mofetil—psoriasis	6.02e-05	0.000272	CcSEcCtD
Daunorubicin—Malaise—Methotrexate—psoriasis	6.02e-05	0.000271	CcSEcCtD
Daunorubicin—Diarrhoea—Hydrocortisone—psoriasis	5.99e-05	0.00027	CcSEcCtD
Daunorubicin—Leukopenia—Methotrexate—psoriasis	5.97e-05	0.000269	CcSEcCtD
Daunorubicin—Urticaria—Dexamethasone—psoriasis	5.94e-05	0.000268	CcSEcCtD
Daunorubicin—Urticaria—Betamethasone—psoriasis	5.94e-05	0.000268	CcSEcCtD
Daunorubicin—Musculoskeletal discomfort—Prednisone—psoriasis	5.93e-05	0.000268	CcSEcCtD
Daunorubicin—Dizziness—Prednisolone—psoriasis	5.93e-05	0.000268	CcSEcCtD
Daunorubicin—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	5.92e-05	0.00126	CbGpPWpGaD
Daunorubicin—Asthenia—Triamcinolone—psoriasis	5.91e-05	0.000267	CcSEcCtD
Daunorubicin—Body temperature increased—Betamethasone—psoriasis	5.91e-05	0.000267	CcSEcCtD
Daunorubicin—Abdominal pain—Betamethasone—psoriasis	5.91e-05	0.000267	CcSEcCtD
Daunorubicin—Abdominal pain—Dexamethasone—psoriasis	5.91e-05	0.000267	CcSEcCtD
Daunorubicin—Body temperature increased—Dexamethasone—psoriasis	5.91e-05	0.000267	CcSEcCtD
Daunorubicin—ABCB1—Allograft Rejection—HLA-A—psoriasis	5.89e-05	0.00125	CbGpPWpGaD
Daunorubicin—Insomnia—Prednisone—psoriasis	5.89e-05	0.000266	CcSEcCtD
Daunorubicin—NR5A1—Developmental Biology—NFKB1—psoriasis	5.87e-05	0.00125	CbGpPWpGaD
Daunorubicin—Nausea—Cyclosporine—psoriasis	5.85e-05	0.000264	CcSEcCtD
Daunorubicin—Pruritus—Triamcinolone—psoriasis	5.83e-05	0.000263	CcSEcCtD
Daunorubicin—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	5.82e-05	0.00124	CbGpPWpGaD
Daunorubicin—Cough—Methotrexate—psoriasis	5.82e-05	0.000263	CcSEcCtD
Daunorubicin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.8e-05	0.00123	CbGpPWpGaD
Daunorubicin—Dizziness—Hydrocortisone—psoriasis	5.79e-05	0.000261	CcSEcCtD
Daunorubicin—Convulsion—Methotrexate—psoriasis	5.78e-05	0.000261	CcSEcCtD
Daunorubicin—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	5.73e-05	0.00122	CbGpPWpGaD
Daunorubicin—Nausea—Mycophenolate mofetil—psoriasis	5.71e-05	0.000258	CcSEcCtD
Daunorubicin—YWHAG—Apoptosis—TP53—psoriasis	5.68e-05	0.00121	CbGpPWpGaD
Daunorubicin—Arthralgia—Methotrexate—psoriasis	5.68e-05	0.000256	CcSEcCtD
Daunorubicin—Chest pain—Methotrexate—psoriasis	5.68e-05	0.000256	CcSEcCtD
Daunorubicin—Myalgia—Methotrexate—psoriasis	5.68e-05	0.000256	CcSEcCtD
Daunorubicin—Decreased appetite—Prednisone—psoriasis	5.66e-05	0.000256	CcSEcCtD
Daunorubicin—YWHAG—Cell Cycle—PCNA—psoriasis	5.66e-05	0.0012	CbGpPWpGaD
Daunorubicin—Rash—Prednisolone—psoriasis	5.65e-05	0.000255	CcSEcCtD
Daunorubicin—Dermatitis—Prednisolone—psoriasis	5.65e-05	0.000255	CcSEcCtD
Daunorubicin—Fatigue—Prednisone—psoriasis	5.62e-05	0.000253	CcSEcCtD
Daunorubicin—Headache—Prednisolone—psoriasis	5.62e-05	0.000253	CcSEcCtD
Daunorubicin—Discomfort—Methotrexate—psoriasis	5.61e-05	0.000253	CcSEcCtD
Daunorubicin—Constipation—Prednisone—psoriasis	5.57e-05	0.000251	CcSEcCtD
Daunorubicin—Vomiting—Hydrocortisone—psoriasis	5.57e-05	0.000251	CcSEcCtD
Daunorubicin—Rash—Hydrocortisone—psoriasis	5.52e-05	0.000249	CcSEcCtD
Daunorubicin—Dermatitis—Hydrocortisone—psoriasis	5.51e-05	0.000249	CcSEcCtD
Daunorubicin—Confusional state—Methotrexate—psoriasis	5.49e-05	0.000248	CcSEcCtD
Daunorubicin—Headache—Hydrocortisone—psoriasis	5.48e-05	0.000248	CcSEcCtD
Daunorubicin—Dizziness—Triamcinolone—psoriasis	5.45e-05	0.000246	CcSEcCtD
Daunorubicin—Anaphylactic shock—Methotrexate—psoriasis	5.44e-05	0.000246	CcSEcCtD
Daunorubicin—Infection—Methotrexate—psoriasis	5.41e-05	0.000244	CcSEcCtD
Daunorubicin—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	5.39e-05	0.00114	CbGpPWpGaD
Daunorubicin—Feeling abnormal—Prednisone—psoriasis	5.37e-05	0.000242	CcSEcCtD
Daunorubicin—Asthenia—Dexamethasone—psoriasis	5.37e-05	0.000242	CcSEcCtD
Daunorubicin—Asthenia—Betamethasone—psoriasis	5.37e-05	0.000242	CcSEcCtD
Daunorubicin—ABCC1—Metabolism—NDUFA5—psoriasis	5.35e-05	0.00114	CbGpPWpGaD
Daunorubicin—Thrombocytopenia—Methotrexate—psoriasis	5.33e-05	0.000241	CcSEcCtD
Daunorubicin—Gastrointestinal pain—Prednisone—psoriasis	5.33e-05	0.00024	CcSEcCtD
Daunorubicin—NR5A1—Developmental Biology—VEGFA—psoriasis	5.33e-05	0.00113	CbGpPWpGaD
Daunorubicin—Nausea—Prednisolone—psoriasis	5.32e-05	0.00024	CcSEcCtD
Daunorubicin—Pruritus—Betamethasone—psoriasis	5.29e-05	0.000239	CcSEcCtD
Daunorubicin—Pruritus—Dexamethasone—psoriasis	5.29e-05	0.000239	CcSEcCtD
Daunorubicin—NR5A1—Developmental Biology—STAT3—psoriasis	5.27e-05	0.00112	CbGpPWpGaD
Daunorubicin—Hyperhidrosis—Methotrexate—psoriasis	5.26e-05	0.000238	CcSEcCtD
Daunorubicin—Vomiting—Triamcinolone—psoriasis	5.24e-05	0.000237	CcSEcCtD
Daunorubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—IL6—psoriasis	5.2e-05	0.0011	CbGpPWpGaD
Daunorubicin—Nausea—Hydrocortisone—psoriasis	5.2e-05	0.000235	CcSEcCtD
Daunorubicin—Rash—Triamcinolone—psoriasis	5.2e-05	0.000235	CcSEcCtD
Daunorubicin—Dermatitis—Triamcinolone—psoriasis	5.19e-05	0.000234	CcSEcCtD
Daunorubicin—Anorexia—Methotrexate—psoriasis	5.19e-05	0.000234	CcSEcCtD
Daunorubicin—YWHAG—SIDS Susceptibility Pathways—IL6—psoriasis	5.18e-05	0.0011	CbGpPWpGaD
Daunorubicin—Urticaria—Prednisone—psoriasis	5.17e-05	0.000234	CcSEcCtD
Daunorubicin—CYP1B1—Metabolism—NDUFA5—psoriasis	5.17e-05	0.0011	CbGpPWpGaD
Daunorubicin—Headache—Triamcinolone—psoriasis	5.16e-05	0.000233	CcSEcCtD
Daunorubicin—Abdominal pain—Prednisone—psoriasis	5.15e-05	0.000232	CcSEcCtD
Daunorubicin—Body temperature increased—Prednisone—psoriasis	5.15e-05	0.000232	CcSEcCtD
Daunorubicin—Diarrhoea—Betamethasone—psoriasis	5.12e-05	0.000231	CcSEcCtD
Daunorubicin—Diarrhoea—Dexamethasone—psoriasis	5.12e-05	0.000231	CcSEcCtD
Daunorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	5.1e-05	0.00108	CbGpPWpGaD
Daunorubicin—ABCC2—Transmembrane transport of small molecules—CP—psoriasis	5.03e-05	0.00107	CbGpPWpGaD
Daunorubicin—ABCC1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.99e-05	0.00106	CbGpPWpGaD
Daunorubicin—ABCC1—Transmembrane transport of small molecules—CP—psoriasis	4.97e-05	0.00106	CbGpPWpGaD
Daunorubicin—Musculoskeletal discomfort—Methotrexate—psoriasis	4.96e-05	0.000224	CcSEcCtD
Daunorubicin—Dizziness—Dexamethasone—psoriasis	4.95e-05	0.000223	CcSEcCtD
Daunorubicin—Dizziness—Betamethasone—psoriasis	4.95e-05	0.000223	CcSEcCtD
Daunorubicin—Insomnia—Methotrexate—psoriasis	4.92e-05	0.000222	CcSEcCtD
Daunorubicin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	4.91e-05	0.00104	CbGpPWpGaD
Daunorubicin—CYP1A1—Aryl Hydrocarbon Receptor—TNF—psoriasis	4.91e-05	0.00104	CbGpPWpGaD
Daunorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	4.9e-05	0.00104	CbGpPWpGaD
Daunorubicin—Nausea—Triamcinolone—psoriasis	4.9e-05	0.000221	CcSEcCtD
Daunorubicin—TOP2A—Circadian rythm related genes—JUN—psoriasis	4.89e-05	0.00104	CbGpPWpGaD
Daunorubicin—Dyspnoea—Methotrexate—psoriasis	4.85e-05	0.000219	CcSEcCtD
Daunorubicin—Somnolence—Methotrexate—psoriasis	4.84e-05	0.000218	CcSEcCtD
Daunorubicin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	4.84e-05	0.00103	CbGpPWpGaD
Daunorubicin—CYP1B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.82e-05	0.00102	CbGpPWpGaD
Daunorubicin—Hypersensitivity—Prednisone—psoriasis	4.8e-05	0.000217	CcSEcCtD
Daunorubicin—ABCC2—Transmembrane transport of small molecules—CARM1—psoriasis	4.8e-05	0.00102	CbGpPWpGaD
Daunorubicin—Vomiting—Betamethasone—psoriasis	4.76e-05	0.000215	CcSEcCtD
Daunorubicin—Vomiting—Dexamethasone—psoriasis	4.76e-05	0.000215	CcSEcCtD
Daunorubicin—ABCC1—Transmembrane transport of small molecules—CARM1—psoriasis	4.74e-05	0.00101	CbGpPWpGaD
Daunorubicin—Decreased appetite—Methotrexate—psoriasis	4.73e-05	0.000214	CcSEcCtD
Daunorubicin—Rash—Dexamethasone—psoriasis	4.72e-05	0.000213	CcSEcCtD
Daunorubicin—Rash—Betamethasone—psoriasis	4.72e-05	0.000213	CcSEcCtD
Daunorubicin—Dermatitis—Dexamethasone—psoriasis	4.71e-05	0.000213	CcSEcCtD
Daunorubicin—Dermatitis—Betamethasone—psoriasis	4.71e-05	0.000213	CcSEcCtD
Daunorubicin—ABCG2—Metabolism—NDUFA5—psoriasis	4.71e-05	0.000999	CbGpPWpGaD
Daunorubicin—Fatigue—Methotrexate—psoriasis	4.69e-05	0.000212	CcSEcCtD
Daunorubicin—Headache—Betamethasone—psoriasis	4.69e-05	0.000211	CcSEcCtD
Daunorubicin—Headache—Dexamethasone—psoriasis	4.69e-05	0.000211	CcSEcCtD
Daunorubicin—Asthenia—Prednisone—psoriasis	4.67e-05	0.000211	CcSEcCtD
Daunorubicin—SLC22A2—Metabolism—NDUFA5—psoriasis	4.66e-05	0.000989	CbGpPWpGaD
Daunorubicin—Pain—Methotrexate—psoriasis	4.66e-05	0.00021	CcSEcCtD
Daunorubicin—Pruritus—Prednisone—psoriasis	4.61e-05	0.000208	CcSEcCtD
Daunorubicin—CYP1A1—PPARA activates gene expression—PPARG—psoriasis	4.6e-05	0.000978	CbGpPWpGaD
Daunorubicin—NR5A1—Developmental Biology—TNF—psoriasis	4.56e-05	0.000969	CbGpPWpGaD
Daunorubicin—ABCC1—Metabolism—CYP2S1—psoriasis	4.55e-05	0.000966	CbGpPWpGaD
Daunorubicin—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	4.51e-05	0.000957	CbGpPWpGaD
Daunorubicin—Feeling abnormal—Methotrexate—psoriasis	4.49e-05	0.000202	CcSEcCtD
Daunorubicin—Diarrhoea—Prednisone—psoriasis	4.46e-05	0.000201	CcSEcCtD
Daunorubicin—Gastrointestinal pain—Methotrexate—psoriasis	4.45e-05	0.000201	CcSEcCtD
Daunorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	4.45e-05	0.000945	CbGpPWpGaD
Daunorubicin—Nausea—Dexamethasone—psoriasis	4.44e-05	0.000201	CcSEcCtD
Daunorubicin—Nausea—Betamethasone—psoriasis	4.44e-05	0.000201	CcSEcCtD
Daunorubicin—TOP2A—Cell Cycle, Mitotic—PCNA—psoriasis	4.43e-05	0.00094	CbGpPWpGaD
Daunorubicin—CYP1B1—Metabolism—CYP2S1—psoriasis	4.4e-05	0.000934	CbGpPWpGaD
Daunorubicin—NR5A1—Gene Expression—PPARG—psoriasis	4.4e-05	0.000933	CbGpPWpGaD
Daunorubicin—ABCG2—Transmembrane transport of small molecules—CP—psoriasis	4.37e-05	0.000929	CbGpPWpGaD
Daunorubicin—SLC22A2—Transmembrane transport of small molecules—CP—psoriasis	4.33e-05	0.000919	CbGpPWpGaD
Daunorubicin—Urticaria—Methotrexate—psoriasis	4.32e-05	0.000195	CcSEcCtD
Daunorubicin—Dizziness—Prednisone—psoriasis	4.31e-05	0.000194	CcSEcCtD
Daunorubicin—Abdominal pain—Methotrexate—psoriasis	4.3e-05	0.000194	CcSEcCtD
Daunorubicin—Body temperature increased—Methotrexate—psoriasis	4.3e-05	0.000194	CcSEcCtD
Daunorubicin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	4.18e-05	0.000888	CbGpPWpGaD
Daunorubicin—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	4.17e-05	0.000886	CbGpPWpGaD
Daunorubicin—Vomiting—Prednisone—psoriasis	4.14e-05	0.000187	CcSEcCtD
Daunorubicin—SLC22A2—Transmembrane transport of small molecules—CARM1—psoriasis	4.13e-05	0.000877	CbGpPWpGaD
Daunorubicin—Rash—Prednisone—psoriasis	4.11e-05	0.000185	CcSEcCtD
Daunorubicin—Dermatitis—Prednisone—psoriasis	4.1e-05	0.000185	CcSEcCtD
Daunorubicin—Headache—Prednisone—psoriasis	4.08e-05	0.000184	CcSEcCtD
Daunorubicin—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	4.03e-05	0.000855	CbGpPWpGaD
Daunorubicin—Hypersensitivity—Methotrexate—psoriasis	4.01e-05	0.000181	CcSEcCtD
Daunorubicin—XDH—Metabolism—CARM1—psoriasis	4.01e-05	0.000851	CbGpPWpGaD
Daunorubicin—ABCG2—Metabolism—CYP2S1—psoriasis	4e-05	0.00085	CbGpPWpGaD
Daunorubicin—SLC22A2—Metabolism—CYP2S1—psoriasis	3.96e-05	0.000841	CbGpPWpGaD
Daunorubicin—TOP2A—Cell Cycle—PCNA—psoriasis	3.96e-05	0.000841	CbGpPWpGaD
Daunorubicin—ABCB1—Allograft Rejection—IFNG—psoriasis	3.93e-05	0.000835	CbGpPWpGaD
Daunorubicin—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	3.93e-05	0.000833	CbGpPWpGaD
Daunorubicin—Asthenia—Methotrexate—psoriasis	3.91e-05	0.000176	CcSEcCtD
Daunorubicin—Nausea—Prednisone—psoriasis	3.87e-05	0.000175	CcSEcCtD
Daunorubicin—Pruritus—Methotrexate—psoriasis	3.85e-05	0.000174	CcSEcCtD
Daunorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	3.81e-05	0.00081	CbGpPWpGaD
Daunorubicin—Diarrhoea—Methotrexate—psoriasis	3.72e-05	0.000168	CcSEcCtD
Daunorubicin—NR5A1—Developmental Biology—IL6—psoriasis	3.68e-05	0.000782	CbGpPWpGaD
Daunorubicin—ABCB1—Allograft Rejection—CXCL8—psoriasis	3.66e-05	0.000776	CbGpPWpGaD
Daunorubicin—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	3.65e-05	0.000776	CbGpPWpGaD
Daunorubicin—Dizziness—Methotrexate—psoriasis	3.6e-05	0.000162	CcSEcCtD
Daunorubicin—Vomiting—Methotrexate—psoriasis	3.46e-05	0.000156	CcSEcCtD
Daunorubicin—Rash—Methotrexate—psoriasis	3.43e-05	0.000155	CcSEcCtD
Daunorubicin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	3.43e-05	0.000728	CbGpPWpGaD
Daunorubicin—Dermatitis—Methotrexate—psoriasis	3.43e-05	0.000155	CcSEcCtD
Daunorubicin—Headache—Methotrexate—psoriasis	3.41e-05	0.000154	CcSEcCtD
Daunorubicin—CYP3A5—Metabolism—NDUFA5—psoriasis	3.37e-05	0.000716	CbGpPWpGaD
Daunorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	3.36e-05	0.000714	CbGpPWpGaD
Daunorubicin—Nausea—Methotrexate—psoriasis	3.23e-05	0.000146	CcSEcCtD
Daunorubicin—TOP2A—Circadian rythm related genes—TP53—psoriasis	3.23e-05	0.000686	CbGpPWpGaD
Daunorubicin—CYP1A1—Metabolism—NDUFA5—psoriasis	3.19e-05	0.000676	CbGpPWpGaD
Daunorubicin—ABCB11—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.17e-05	0.000674	CbGpPWpGaD
Daunorubicin—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	3.13e-05	0.000665	CbGpPWpGaD
Daunorubicin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	3.13e-05	0.000665	CbGpPWpGaD
Daunorubicin—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	3.11e-05	0.000659	CbGpPWpGaD
Daunorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.01e-05	0.000639	CbGpPWpGaD
Daunorubicin—CYP1A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.97e-05	0.000631	CbGpPWpGaD
Daunorubicin—ABCB1—Allograft Rejection—VEGFA—psoriasis	2.97e-05	0.000631	CbGpPWpGaD
Daunorubicin—ABCB11—Metabolism—CARM1—psoriasis	2.96e-05	0.000628	CbGpPWpGaD
Daunorubicin—TOP2A—Circadian rythm related genes—IL6—psoriasis	2.96e-05	0.000627	CbGpPWpGaD
Daunorubicin—CYP3A5—Metabolism—CYP2S1—psoriasis	2.87e-05	0.000609	CbGpPWpGaD
Daunorubicin—ABCB11—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.76e-05	0.000587	CbGpPWpGaD
Daunorubicin—CYP1A1—Metabolism—CYP2S1—psoriasis	2.71e-05	0.000575	CbGpPWpGaD
Daunorubicin—ABCB1—Allograft Rejection—TNF—psoriasis	2.55e-05	0.00054	CbGpPWpGaD
Daunorubicin—ABCB1—Metabolism—NDUFA5—psoriasis	2.54e-05	0.00054	CbGpPWpGaD
Daunorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.53e-05	0.000537	CbGpPWpGaD
Daunorubicin—XDH—Metabolism—CAT—psoriasis	2.47e-05	0.000524	CbGpPWpGaD
Daunorubicin—ABCC1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.38e-05	0.000506	CbGpPWpGaD
Daunorubicin—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.37e-05	0.000502	CbGpPWpGaD
Daunorubicin—CYP1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.31e-05	0.000489	CbGpPWpGaD
Daunorubicin—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.26e-05	0.000479	CbGpPWpGaD
Daunorubicin—ABCC1—Metabolism—CARM1—psoriasis	2.22e-05	0.000472	CbGpPWpGaD
Daunorubicin—ABCB1—Metabolism—CYP2S1—psoriasis	2.16e-05	0.000459	CbGpPWpGaD
Daunorubicin—CYP1B1—Metabolism—CARM1—psoriasis	2.15e-05	0.000456	CbGpPWpGaD
Daunorubicin—YWHAG—Cell Cycle—TP53—psoriasis	2.08e-05	0.000442	CbGpPWpGaD
Daunorubicin—ABCC1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.08e-05	0.000441	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism—NDUFA5—psoriasis	2.03e-05	0.000431	CbGpPWpGaD
Daunorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.01e-05	0.000426	CbGpPWpGaD
Daunorubicin—ABCG2—Metabolism—CARM1—psoriasis	1.95e-05	0.000415	CbGpPWpGaD
Daunorubicin—SLC22A2—Metabolism—CARM1—psoriasis	1.93e-05	0.000411	CbGpPWpGaD
Daunorubicin—XDH—Metabolism—APOE—psoriasis	1.92e-05	0.000407	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.89e-05	0.000402	CbGpPWpGaD
Daunorubicin—ABCB11—Metabolism—CAT—psoriasis	1.82e-05	0.000386	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism—CYP2S1—psoriasis	1.73e-05	0.000367	CbGpPWpGaD
Daunorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.68e-05	0.000356	CbGpPWpGaD
Daunorubicin—XDH—Metabolism—PPARG—psoriasis	1.67e-05	0.000354	CbGpPWpGaD
Daunorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.61e-05	0.000343	CbGpPWpGaD
Daunorubicin—CYP3A4—Metabolism—NDUFA5—psoriasis	1.57e-05	0.000333	CbGpPWpGaD
Daunorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.47e-05	0.000311	CbGpPWpGaD
Daunorubicin—TOP2A—Cell Cycle—TP53—psoriasis	1.46e-05	0.000309	CbGpPWpGaD
Daunorubicin—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.42e-05	0.000301	CbGpPWpGaD
Daunorubicin—ABCB11—Metabolism—APOE—psoriasis	1.41e-05	0.0003	CbGpPWpGaD
Daunorubicin—CYP3A5—Metabolism—CARM1—psoriasis	1.4e-05	0.000297	CbGpPWpGaD
Daunorubicin—ABCC1—Metabolism—CAT—psoriasis	1.37e-05	0.00029	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—HLA-A—psoriasis	1.36e-05	0.000288	CbGpPWpGaD
Daunorubicin—CYP3A4—Metabolism—CYP2S1—psoriasis	1.33e-05	0.000283	CbGpPWpGaD
Daunorubicin—CYP1A1—Metabolism—CARM1—psoriasis	1.32e-05	0.000281	CbGpPWpGaD
Daunorubicin—CYP1B1—Metabolism—CAT—psoriasis	1.32e-05	0.000281	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—APOE—psoriasis	1.27e-05	0.000269	CbGpPWpGaD
Daunorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.26e-05	0.000267	CbGpPWpGaD
Daunorubicin—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.24e-05	0.000263	CbGpPWpGaD
Daunorubicin—ABCB11—Metabolism—PPARG—psoriasis	1.23e-05	0.000261	CbGpPWpGaD
Daunorubicin—ABCG2—Metabolism—CAT—psoriasis	1.2e-05	0.000255	CbGpPWpGaD
Daunorubicin—SLC22A2—Metabolism—CAT—psoriasis	1.19e-05	0.000253	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—NOS2—psoriasis	1.18e-05	0.000251	CbGpPWpGaD
Daunorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.11e-05	0.000235	CbGpPWpGaD
Daunorubicin—ABCC1—Metabolism—APOE—psoriasis	1.06e-05	0.000225	CbGpPWpGaD
Daunorubicin—ABCB1—Metabolism—CARM1—psoriasis	1.06e-05	0.000224	CbGpPWpGaD
Daunorubicin—CYP1B1—Metabolism—APOE—psoriasis	1.03e-05	0.000218	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—TYK2—psoriasis	9.67e-06	0.000205	CbGpPWpGaD
Daunorubicin—ABCG2—Metabolism—APOE—psoriasis	9.34e-06	0.000198	CbGpPWpGaD
Daunorubicin—ABCC1—Metabolism—PPARG—psoriasis	9.25e-06	0.000196	CbGpPWpGaD
Daunorubicin—SLC22A2—Metabolism—APOE—psoriasis	9.24e-06	0.000196	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.05e-06	0.000192	CbGpPWpGaD
Daunorubicin—CYP1B1—Metabolism—PPARG—psoriasis	8.94e-06	0.00019	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—CD4—psoriasis	8.75e-06	0.000186	CbGpPWpGaD
Daunorubicin—CYP3A5—Metabolism—CAT—psoriasis	8.61e-06	0.000183	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism—CARM1—psoriasis	8.44e-06	0.000179	CbGpPWpGaD
Daunorubicin—CYP1A1—Metabolism—CAT—psoriasis	8.14e-06	0.000173	CbGpPWpGaD
Daunorubicin—ABCG2—Metabolism—PPARG—psoriasis	8.14e-06	0.000173	CbGpPWpGaD
Daunorubicin—SLC22A2—Metabolism—PPARG—psoriasis	8.05e-06	0.000171	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.89e-06	0.000167	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—STAT3—psoriasis	6.77e-06	0.000144	CbGpPWpGaD
Daunorubicin—CYP3A5—Metabolism—APOE—psoriasis	6.69e-06	0.000142	CbGpPWpGaD
Daunorubicin—CYP3A4—Metabolism—CARM1—psoriasis	6.51e-06	0.000138	CbGpPWpGaD
Daunorubicin—ABCB1—Metabolism—CAT—psoriasis	6.5e-06	0.000138	CbGpPWpGaD
Daunorubicin—CYP1A1—Metabolism—APOE—psoriasis	6.32e-06	0.000134	CbGpPWpGaD
Daunorubicin—CYP3A5—Metabolism—PPARG—psoriasis	5.83e-06	0.000124	CbGpPWpGaD
Daunorubicin—CYP1A1—Metabolism—PPARG—psoriasis	5.51e-06	0.000117	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism—CAT—psoriasis	5.19e-06	0.00011	CbGpPWpGaD
Daunorubicin—ABCB1—Metabolism—APOE—psoriasis	5.05e-06	0.000107	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—IL6—psoriasis	4.73e-06	0.0001	CbGpPWpGaD
Daunorubicin—ABCB1—Metabolism—PPARG—psoriasis	4.4e-06	9.34e-05	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism—APOE—psoriasis	4.03e-06	8.56e-05	CbGpPWpGaD
Daunorubicin—CYP3A4—Metabolism—CAT—psoriasis	4e-06	8.5e-05	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism—PPARG—psoriasis	3.51e-06	7.46e-05	CbGpPWpGaD
Daunorubicin—CYP3A4—Metabolism—APOE—psoriasis	3.11e-06	6.61e-05	CbGpPWpGaD
Daunorubicin—CYP3A4—Metabolism—PPARG—psoriasis	2.71e-06	5.75e-05	CbGpPWpGaD
